Related Experiment Video
Updated: Jun 21, 2025
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer
Hao Fan1, Xuefei Hu2, Fuao Cao1
1Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Abstract:
Protein tyrosine phosphatase SHP2 activates RAS signaling, which is a novel target for colorectal cancer (CRC) therapy. However, SHP2 inhibitor monotherapy is ineffective for metastatic CRC and a combination therapy is required. In this study, we aimed to improve the antitumor efficacy of SHP2 inhibition and try to explore the resistance mechanism of SHP2 inhibitor. Results showed that WWP1 promoted the proliferation of CRC cells. Genetic or pharmacological inhibition of WWP1 enhanced the effect of SHP2 inhibitor in suppressing tumor growth in vitro and in vivo. WWP1 may mediate feedback reactivation of AKT signaling following SHP2 inhibition. Furthermore, nomogram models constructed with IHC expression of WWP1 and SHP2 greatly improved the accuracy of prognosis prediction for patients with CRC. Our findings indicate that WWP1 inhibitor I3C can synergize with SHP2 inhibitor and is expected to be a new strategy for clinical trials in treating advanced CRC patients.
Insights
Combining WWP1 inhibition with SHP2 inhibitors shows promise for treating advanced colorectal cancer (CRC). This strategy overcomes resistance and improves antitumor efficacy, offering a new therapeutic approach for CRC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Protein tyrosine phosphatase SHP2 is a key activator of RAS signaling and a potential therapeutic target for colorectal cancer (CRC).
- SHP2 inhibitor monotherapy demonstrates limited efficacy in metastatic CRC, necessitating combination strategies to enhance antitumor effects.
- Understanding resistance mechanisms to SHP2 inhibition is crucial for developing effective CRC treatments.
Purpose of the Study:
- To enhance the antitumor efficacy of SHP2 inhibition in colorectal cancer.
- To investigate the role of WWP1 in colorectal cancer progression and resistance to SHP2 inhibitors.
- To explore WWP1 as a potential therapeutic target in combination with SHP2 inhibitors for CRC treatment.
Main Methods:
- Assessed the role of WWP1 in CRC cell proliferation using genetic and pharmacological inhibition.
- Evaluated the synergistic effects of WWP1 and SHP2 inhibition on tumor growth in vitro and in vivo.
- Investigated the impact of WWP1 inhibition on AKT signaling feedback reactivation following SHP2 inhibition.
- Developed nomogram models based on WWP1 and SHP2 immunohistochemistry (IHC) expression for prognosis prediction in CRC patients.
Main Results:
- WWP1 was found to promote colorectal cancer cell proliferation.
- Inhibition of WWP1 significantly enhanced the antitumor effects of SHP2 inhibitors in both in vitro and in vivo models.
- WWP1 inhibition appeared to prevent feedback reactivation of AKT signaling after SHP2 inhibition.
- Nomogram models incorporating WWP1 and SHP2 IHC expression demonstrated improved accuracy in predicting CRC patient prognosis.
Conclusions:
- WWP1 inhibition synergizes with SHP2 inhibitors to suppress colorectal cancer growth, suggesting a novel combination therapy approach.
- WWP1 plays a critical role in mediating resistance to SHP2 inhibitors, potentially through AKT signaling.
- The combination of WWP1 inhibitor I3C with SHP2 inhibitors holds potential for clinical trials in advanced CRC.
- WWP1 and SHP2 expression levels can serve as valuable biomarkers for predicting CRC prognosis.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
